Robert M. Rifkin

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian W. Flinn, Paul G. Richardson et al. · Blood · 2012 · 449 citations · Full text

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

Raymond B. Weiss, Robert M. Rifkin, F. Marc Stewart et al. · The Lancet · 2000 · 163 citations

Breast Oncology, Oncology, Bezwoda Study +6

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Journal of Clinical Oncology · 2015 · 151 citations

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma

Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher et al. · Cancer · 2006 · 131 citations